Compare Gilead Sciences, Inc. (GILD) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs United States Oil ETF — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while United States Oil ETF trades at $148.2 (market cap $1.90B). The key difference: Gilead Sciences, Inc. is far larger — about 96× United States Oil ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while United States Oil ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and United States Oil ETF for 21 Days on average.
| GILD | USO | |
|---|---|---|
Market Cap | $182.40B | $1.90B |
Volume | 4,469,821 | 5,932,922 |
Sector | Health | — |
52-Week High | $155.80 | $161.86 |
52-Week Low | $117.18 | $66.17 |
Typical Hold Time | 111 Days | 21 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 0.17% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have mostly beaten expectations, though Q2 2026 saw a significant loss. The company maintains robust operating cash flow and has expanded access to its HIV prevention drug lenacapavir in Latin America, signaling growth potential in its core franchises.
The outlook is positive given analyst buy ratings and a $151.57 price target, but risks include negative net income margin and ROE in 2026, high debt levels, and reliance on pipeline success. The stock offers value if HIV and oncology advances materialize, yet investors face volatility from earnings inconsistencies and competitive pressures.
USO is trading at $147.58, up 2.55% with a bullish technical signal supported by moving averages. Recent news highlights mixed oil price movements amid Middle East tensions and OPEC+ maintaining steady output. The stock shows strength above key support levels with neutral oscillators suggesting balanced momentum.
The outlook remains cautiously optimistic given geopolitical risks and supply dynamics. Key opportunities include potential price support from production disruptions, while risks involve volatility from geopolitical events and coordinated reserve releases pressuring prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
